NovoCure Ltd

The company develops and commercializes tumor treating fields (TTFields), a treatment modality that uses electric fields to disrupt cancer cell division. NovoCure manufactures and markets two primary TTFields devices: Optune Gio and Optune Lua, which are used in the treatment of solid tumor cancers. The company generates revenue primarily through device sales and related treatment services. Current clinical trials are investigating TTFields applications across multiple cancer types, including brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.

NovoCure operates with approximately 1,488 full-time employees and maintains its headquarters in Baar, Switzerland. The company maintains a commercial presence across North America, Europe, and Asia-Pacific regions, including the United States, Germany, France, Japan, and Greater China. The organization was incorporated in 2000 and is listed on the Nasdaq exchange with a market capitalization of $1.3 billion.